Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021). In oral and […]
Philadelphia, PA, October 28, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational […]
Spirovant leases its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City and welcomes the appointments of Eric Pastor as Senior Vice President of Technology Development and Operations and Maria Limberis, PhD, as Vice President of Research